
MEDNAX (MD) Stock Forecast & Price Target
MEDNAX (MD) Analyst Ratings
Bulls say
Pediatrix Medical Group Inc. has demonstrated robust performance, with a reported 6.2% same-store growth in the first quarter of 2025, continuing the positive momentum from the second half of 2024, primarily driven by pricing strength. Additionally, improvements in margins and cash flow are anticipated as a result of recent portfolio restructurings and a transition to revenue cycle management. Furthermore, the company has revised its adjusted EPS estimates for 2025 and 2026 upward, increasing from $1.54 to $1.72 and from $1.80 to $1.84, indicating a favorable outlook on profitability moving forward.
Bears say
Pediatrix Medical Group's stock faces a negative outlook due to its business model being heavily reliant on U.S. birth rates, which have been trending downward, leading to expected ongoing headwinds. Additionally, the neonatal segment of the company exhibits limited organic growth potential and struggles with expansion into new specialty areas, potentially affecting consistent revenue growth and profit margins. Lastly, internal compensation structures may create friction among physicians, complicating recruitment efforts, while external factors such as regulatory changes and reimbursement rate shifts may further jeopardize revenue stability.
This aggregate rating is based on analysts' research of MEDNAX and is not a guaranteed prediction by Public.com or investment advice.
MEDNAX (MD) Analyst Forecast & Price Prediction
Start investing in MEDNAX (MD)
Order type
Buy in
Order amount
Est. shares
0 shares